Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Tasly Biopharmaceuticals / Equity Capital Markets

Tasly Biopharm, a biologics R&amp;D platform spin-off from A-share listed <a href="https://www.smartkarma.com/entities/tasly-pharmaceutical-group-co" target="_blank" data-smartkarma-citation="entities:9569:1" rel="noopener">Tasly Pharmaceutical Group (600535 CH)</a>, is looking to raise up to USD 1 bn via a listing in Hong Kong.
In this insight, we will cover the company background, the key products that have reached the clinical trial stage, and the company's shareholders and investors.
We think the company has demonstrated its capability of completing R&amp;D and commercializing a product. The future growth from pro-UK series of drugs is visible as the clinical trials progress. But at the same time, we don't see opportunities for exponential growth from blockbuster products.

Tasly Biopharm, a biologics R&amp;D platform spin-off from A-share listed Tasly Pharmaceutical Group (600535 CH), is looking to raise up to USD 1 bn via a listing in Hong Kong.
In this insight, we will cover the company background, the key products that have reached the clinical trial stage, and the company's shareholders and investors.
We think the company has demonstrated its capability of completing R&amp;D and commercializing a product. The future growth from pro-UK series of drugs is visible as the clinical trials progress. But at the same time, we don't see opportunities for exponential growth from blockbuster products.

Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters